Ocrevus vs Tecfidera
Side-by-side cost comparison based on Medicare Part D data
Ocrevus
Ocrelizumab
Manufactured by Genentech/Roche
Tecfidera
Dimethyl Fumarate
Manufactured by Biogen
Tecfidera costs 83% less per claim than Ocrevus ($4,103.00 vs $23,635.00). A generic version of Tecfidera is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Ocrevus | Tecfidera |
|---|---|---|
| Avg Cost Per Claim | $23,635.00 | $4,103.00 |
| Total Medicare Spending | $3.5B | $1.8B |
| Total Beneficiaries | 62,000 | 38,000 |
| Total Claims | 148,000 | 428,000 |
| Annual Cost/Patient | $56,419.00 | $46,211.00 |
| Year-over-Year Change | +16.5% | -28.4% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Apr 12, 2024 |
| Manufacturer | Genentech/Roche | Biogen |
| Condition | Multiple Sclerosis | Multiple Sclerosis |
| Generic Name | Ocrelizumab | Dimethyl Fumarate |
Ocrevus vs Tecfidera: What the Data Shows
Ocrevus (Ocrelizumab) and Tecfidera (Dimethyl Fumarate) are both used to treat multiple sclerosis. Based on Medicare Part D data, Tecfidera costs $4,103.00 per claim, which is 83% less than Ocrevus at $23,635.00 per claim.
Medicare spent $3.5B on Ocrevus and $1.8B on Tecfidera. In terms of patient reach, Ocrevus serves more beneficiaries (62,000 vs 38,000).
Year-over-year spending changed +16.5% for Ocrevus and -28.4% for Tecfidera. Ocrevus saw significant spending growth, suggesting increased utilization or price increases.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Tecfidera is cheaper at $4,103.00 per claim, compared to $23,635.00 for Ocrevus. That makes Tecfidera about 83% less expensive per claim based on Medicare Part D data.
Yes, both Ocrevus and Tecfidera are used to treat multiple sclerosis. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Ocrelizumab and generic Dimethyl Fumarate can offer significant cost savings — typically 80-95% less than the brand name.
Medicare Part D spent $3.5B on Ocrevus covering 62,000 beneficiaries, and $1.8B on Tecfidera covering 38,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.